FDA adds clinical pharmacology to growing pile of biosimilar guidances
This article was originally published in Scrip
The US FDA has published another draft guidance on biosimilar product development, this time on clinical pharmacology studies, which the agency says will help companies design studies to show that there are no "clinically meaningful differences" between the biosimilar and its reference drug.
You may also be interested in...
Early interaction with the European Medicines Agency is recommended if companies are planning to incorporate digital technologies into their drug development plans.
The latest global vaccines summit has seen the launch of a new mechanism designed to spur the development of new coronavirus vaccines and ensure they are made available, particularly in low- and middle-income countries.
Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.